Carol Cheng, COO of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), provides insights into the recent development of the country’s innovative biopharmaceutical industry, while she also highlights TRPMA’s eye-catching initiative to promote international collaboration between Taiwan’s academia and the global industry, thanks to the recent set up of the association’s BioIPSeeds® platform, which proudly stands as the first application of the blockchain technology into the biopharmaceutical field.
You have been heading TRPMA since it was founded in November 2012. What are the association’s main mandates?
"There is a crucial need to develop Taiwan’s Open Innovation culture, as such collaborative approach encompassing both academia and the industry hasn’t yet been embedded deep enough in the roots of our healthcare sector."
